Dermatology is foundational to our identity and remains a core innovation focus. We began with a pioneering anti-fungal range of products and today our clinical focus spans across chronic and complex dermatological conditions including eczema, acne vulgaris, vitiligo, psoriasis, fungal infections, and scalp disorders. Backed by clinical rigour, dermatologist confidence, and a deep understanding of diverse skin types and treatment needs, today we are category leaders in multiple markets.

With Ichnos Glenmark Innovation (IGI), we have further strengthened our innovation-driven approach. Through our partnership with Almirall, our first-in-class IL-1RAP antagonist ISB 880, is now in Phase 2 of clinical development for the treatment of Hidradenitis Suppurativa. Our OX40 antagonist, ISB 830-KB, for atopic dermatitis is being advanced through our global partnership with Astria. These partnerships underscore the depth of our scientific rigor and innovation capabilities.With a scaled global presence, we remain focused on expanding access to high-quality dermatology therapies across age groups, climate conditions, and skin profiles, improving outcomes for millions of patients worldwide.

A flagship example of this innovation is WINLEVI^®, a first-in-class topical androgen receptor inhibitor approved for the treatment of acne vulgaris. By targeting androgen signalling directly in the skin, WINLEVIM^® represents a novel, non-systemic approach to acne management, addressing an important gap in existing treatment options.